Stefan Yee

chairman and non – executive director

Mr. Stefan Yee has more than 30 years of experience in audit, corporate law, mergers and acquisitions, corporate finance.

Mr. Stefan Yee has more than 30 years of experience in audit, corporate law, mergers and acquisitions, corporate finance, investment banking and private equity with companies as KPMG, Linklaters, the Flemish investment bank Lessius, the Belgian Corporation for International Investment (SBI/BMI), Beluga (Euronext Brussels) and as the founder and CEO of the PE Group, a Belgian privately held private equity firm. Stefan is, and has been an investor and/or board member of several listed and private companies such as, amongst others, Beluga, Encare group (Mensura), AXI, The Reference, Alro Holdings, Loomans Group, United Brands, Capco, Faseas International (Spacewell), HD Partners (Dekabo group), AED Rent, UnifiedPost Group, NRG New Generation, Axiles Bionics, including several healthcare companies (Docpharma (formerly Euronext Brussels), Uteron Pharma and Imcyse). Stefan holds Masters degrees in Law and Business Management from the Universities of Brussels (VUB and ULB Solvay Business School) and the University of Chicago (as a BAEF Fellow).

Leon Van Rompay

non – executive director

Leon Van Rompay has more than 40 years’ experience in the pharmaceutical market. During his professional career he served in.

Leon Van Rompay has more than 40 years’ experience in the pharmaceutical market. During his professional career he served in several positions including country & area manager (covering major territories) and board member of the Zambon Group. He was founder and CEO of Docpharma, a Belgian based generics company that was listed on Euronext and served on different boards including Ecodis and Uteron Pharmaceuticals. He was a founding member of BIGE/IBES (Belgian Institute for Health and Economics), the B.G.A. (Belgian Generic Association), BAPIE (Belgian Association of Parallel Import and Export) and was an executive committee member and board member of the Belgian Pharmaceutical Industry Association. He also was a member of the pharmaceutical deontological commission and responsible for this commission in the industry association executive committee.

Marc Foidart

independent director

Marc Foidart obtained a Master in Business Engineering from the University of Liège (1998). He is co-founder of EKLO ASBL.

Marc Foidart obtained a Master in Business Engineering from the University of Liège (1998). He is co-founder of EKLO ASBL, Member of the Executive Committee of Noshaq SA in charge of the Life Sciences sector, CEO of B2H SA, the public company superseding the Liege life sciences ecosystem, and Investment Manager of Epimede SA, a EUR 50 million Belgian based private high-tech growth fund. He has more than 15 years of experience in strategic consulting and investment at all stages of development of small and medium high tech- high growth life sciences enterprises. He played a key role in several financing rounds at critical development stages of various Belgian young biotech companies among which: Mithra Pharmaceuticals SA, Imcyse SA, Uteron Pharma SA, PDC Line Pharma SA, Diagenode SA. As an entrepreneur, Marc Foidart is Co-Founder and past CEO of Arlenda SA, a spin-off company of the University of Liège providing expert statistical solutions to the pharmaceutical, chemical and environment industries. He is also Co-Founder and Executive Chairman of Eyed Pharma SA, a start-up company developing innovative controlled release microimplants in ophthalmology. Marc Foidart has been associate professor at the University of Liege since 2011.

Carolyn Myers

independent director

Dr. Carolyn Myers is an accomplished senior executive with extensive experience creating, growing, and leading health care.

Dr. Carolyn Myers is an accomplished senior executive with extensive experience creating, growing, and leading health care businesses. She is currently Principal of Bioensemble Ltd, a business strategy consulting firm that advises C-suite executives of small and medium size companies on a comprehensive range of drug development, commercial and business development services. Carolyn’s experience comes from having led many businesses in their growth strategies. At Allergan (formerly Actavis), she was the Vice President of Global Business Development and Alliance Management with a focus on expanding product portfolios. At Forest Laboratories (acquired by Actavis), Carolyn was the Vice President of the CNS marketing group responsible for marketing and sales of established and new products. At Mylan she held two different leadership positions including

President of Mylan Technologies, a division focused on developing generic transdermal systems and President of Dey Laboratories having full P&L responsibility to develop, manufacture and sell innovative respiratory products. Carolyn is also an advisor to several start-up organizations and capital investors.

Carolyn earned a PhD in Genetics from the University of British Columbia and an MBA from Rutgers University.

James Gale

independent director

James (Jim) Gale is the founding partner of Signet Healthcare Partners. Jim has over 30 years of healthcare investing and finance experience.

Jim is a Managing Director in Signet Fund IV and is currently the Chairman of the Board of Alpex Pharma S.A., Knight Therapeutics Inc. (TSX: GUD), Teligent (NSDQ: TLGT, formerly IGI Laboratories), and also serves on the Board of Directors of Bionpharma, Chr. Olesen Synthesis A/S, CoreRx, LeonNanodrugs GmbH, Pharmaceutics International (Pii), Advantice Health, and RK Pharma. Prior portfolio company boards include Arbor Pharmaceuticals, Amarin Corporation, eResearch Technologies Inc., and Valera Pharmaceuticals.

Prior to founding Signet, Jim was head of principal investment activities and head of investment banking for Gruntal & Co., LLC. While at Gruntal, he made a number of investments including Andrx Corporation, Royce Laboratories (merged with Watson Pharmaceuticals), Lifecell Corporation, Neurocrine Biosciences, and BML Pharmaceuticals (acquired by Endo Pharmaceuticals).

Chris Buyse

Independent Director

Chris Buyse has more than 30 years of international expertise across the healthcare sector.

Chris is currently Managing Director of Fund+, the largest Belgian life sciences-dedicated venture capital fund and serves as member of the board of directors of several European companies listed on Nasdaq and Euronext, including iTeos Therapeutics, Celyad and Inventiva Pharma. Chris is also a Director of the Francqui Foundation, among other private mandates. Chris holds a Master’s Degree in applied economic sciences from the University of Antwerp, and an MBA from the Vlerick School of Management in Ghent.

Stijn Van Rompay

chief executive officer & co-founder

Mr. Stijn Van Rompay has over 20 years of experience in leadership positions at various pharmaceutical companies.

Stijn co-founded and was the CEO of Alter Pharma, a pharmaceutical company focused on the development of complex generics and pharmacy-related product sales. He was also co-CEO of Uteron Pharma, a company focused on innovative female healthcare products.

Prior to these positions, Stijn was CFO and later, CEO of Docpharma (formerly quoted on Euronext Brussels) a generics and medical-device company. Under his leadership, the companies recorded strong growth and value creation. He also holds several non-executive director positions in the biotech sector, and acts as an advisor to venture capital investors. Stijn holds a Master’s degree in Applied Economics from the University of Antwerp.

Thomas Jacobsen

chief business development officer & co-founder

Mr. Thomas Jacobsen has over 20 years of experience in the pharmaceutical industry, with expertise in operational management, business development, licensing, and research and development.

He co-founded Alter Pharma, a pharmaceutical company focused on the development of complex generics and pharmacy-related product distribution. Prior to this, he worked with Docpharma, a generics and medical-device company that was acquired by Matrix Laboratories/Mylan Laboratories, where he worked on out-licensing of Docpharma’s products. Thomas started his career in the Scandinavian-based generics company Alternova, where he was responsible for licensing, product registration and launches. Thomas holds a Master’s Degree in Pharmacy from the University of Copenhagen and a Business Degree from Copenhagen Business School.

Jean-Luc Vandebroek

Chief Financial Officer

Jean-Luc Vandebroek is a seasoned executive who joined us in September 2021 from his role as CFO of Bone Therapeutics, a publicly traded biotech company based in Gosselies, Belgium. Prior to that, he was CFO and CIO at Alcopa and Fluxys, and before that, he held various senior financial positions at Delhaize Group. Jean-Luc is an experienced Executive Board member and has a track record of developing and implementing financing strategies and transactions and has a large, global network of investors and financial institutions. Jean-Luc holds a Master in Business Administration from the Louvain Management School.

Dietmar Aichhorn

chief operating officer

Dr. Dietmar Aichhorn, PhD, has over 20 years of experience in various scientific roles within the pharmaceutical industry.

Over the course of his career at Sandoz, Mylan, Innovacell, ViraTherapeutics and Polpharma Biologics, Dietmar has held several senior management positions of increasing responsibilities including Head Clinical Development and Head Development. Dr. Dietmar Aichhorn is an expert in the fields of technical development, clinical development and regulatory affairs in the US, EU and other key geographies. Most recently, Dietmar had an assignment at Polpharma Biologics, where he was responsible for the clinical development of monoclonal antibodies, as well as overseeing all scientific affairs. Dietmar graduated as chemical engineer in Linz but has perfected his project management skills at the university of Vienna.

Koenraad Van der Elst

chief legal officer

Mr. Koenraad Van der Elst has more than 30 years of experience as an in-house and external legal and general counsellor for various listed companies.

Koenraad served as General Counsel at Metris (currently Nikon Metrology), and acted as Secretary General & General Counsel of PUNCH INTERNATIONAL, a Belgian company listed on Euronext Brussels. He was also General Counsel & Secretary to the Board of PUNCH GRAPHIX plc, a company listed on the London Stock Exchange (AIM), and President of the Supervisory Board of PUNCH TECHNIX, a company listed on Euronext Amsterdam. Between 1995 and 2002, Koenraad was the Director of Legal Documentation at the Investment Banking Department (corporate finance & capital markets) of Generale Bank/Fortis Bank and was involved in most capital market transactions in Belgium (take-over bids, exchange offers, initial public offerings, etc.), as well as in a large number of corporate finance deals (M&A, advisory, fairness opinions, mergers, restructurings, etc.), at local, cross-border and international levels.

In addition, Koenraad was an assistant Professor at the University of Brussels (VUB) in Financial Law. He holds a law degree from the University of Brussels (VUB) and an MBA from EHSAL Brussels.

Grow with us

We are driven to continuously innovate existing medications and offer meaningful benefits to patients, physicians and payors.

Why join us

The key to success is an exceptional workforce. Great people generate great results. As a young, entrepreneurial company, Hyloris fosters creativity, courage, and professionalism.
At Hyloris you will be part of multicultural and multidisciplinary team who will support you to further develop and grow your personal skills.

We strive to create an exciting and dynamic working environment in which you will be challenged to take initiative, contributing to the success of the company.

Interested in joining our mission to address important healthcare needs and deliver relevant improvements for patients, healthcare professionals and payors? Check out our vacancies below.

We look forward to hearing from you.

Latest vacancies

Licensing Manager

Location: Anywhere

view vacancy

We are currently looking for a Licensing Manager. The successful candidate will be responsible and contribute to the definition and execute the implementation of the licensing strategy of Hyloris.

He/she will report into the Chief Business Development Officer.

The job description

As Licensing Manager you will:

  • Develop and implement the Licensing Strategy
  • Conduct market research and analysis to identify licensing opportunities and potential partners.
  • Collaborate with company management to align licensing strategy with overall business objectives.
    • Develop a roadmap for licensing activities, including timelines, milestones, and performance indicators.
    • Monitor industry trends and competitor activities to identify potential threats and opportunities.
    • Continuously evaluate and refine the licensing strategy based on market feedback, and changes in the business environment.
    • Communicate the licensing strategy to relevant internal teams and ensure their understanding and alignment with the objectives.
  • Manage Licensing Management
    • Manage licensing activities for selected markets and clients.
    • Manage the company’s commercial material, including info for the website and the LinkedIn responsible.
    • Identify potential clients for the company’s portfolio.
    • Prepare, present, and negotiate proposals.
    • Negotiate and finalize contracts.
    • Organize and participate in industry events.
  • Report Analytics
    • Provide weekly progress reports to the direct manager.
    • Ensure company-wide communication of key licensing updates.
    • Develop annual sales budget for licenses and products for the upcoming year.
    • Implement plans to achieve annual sales targets in line with company strategy, monitor performance, and adjust as needed.
  • Implement Process Improvement and contribute to the Team Collaboration
    • Evaluate and optimize communication and information flow between stakeholders.
    • Identify bottlenecks, recommend solutions, and collaborate with other departments to improve workflow.
  • Foster a company culture that embraces openness, dialogue, and feedback.

Your professional profile

  • Minimum Qualification: Bachelor’s degree in business or in related field; Extensive experience with EU licensing preferred.
  • Minimum Experience: Significant experience in a pharmaceutical industry, specifically within commercial department in a generic company
  • Languages: Proficiency in English, both written and spoken, is required.

Your abilities

  • Demonstrated strategic mindset and strong communication skills, with a positive and proactive attitude.
  • Sensitivity to and respect for cultural differences, and the ability to work effectively in a multicultural environment.
  • Capacity to manage and support teams both in-person and remotely, adapting to diverse working styles.
  • Proven track record in licensing, with attention to detail and the ability to see the bigger picture.
  • Strong interpersonal skills with the ability to influence others in a positive and effective manner,
  • Strong negotiation and closing skills.

About Our Company

Based in Liège, Belgium, Hyloris is an early-stage innovative specialty pharmaceutical company focused on adding value to the healthcare system by reformulating well-known pharmaceuticals. Hyloris develops proprietary products it believes offer significant advantages compared to currently available alternatives, with the aim to address the underserved medical needs of patients, hospitals, physicians, payors and other stakeholders in the healthcare system.

Hyloris has a robust management team with a success track record from many years in the pharmaceutical industry. We have a full operational structure with departments for Business Development, R&D, Regulatory, Medical Affairs and Licensing.

Hyloris is listed on Euronext Brussels.

Our values

Our talented staff work in accordance with our company values:

  • We are proud of our entrepreneurial culture.
  • We foster open communication, mutual respect, professionalism and efficient decision-making.
  • We believe that our multicultural organisation is an important competitive advantages.
  • We believe that timely and well considered decisions as a response to emerging opportunities and ideas is the key to our success.
  • We believe that the success of the company lies in the competence, dedication and motivation of each of our employees.
  • We believe that freedom returns flexibility and empowerment returns commitment.

About Our Business Development Department

Our Business Development department consist of 8 employees, working in our Belgian office, in Europe and from the US. We work on a unique pipeline of more than 15 value added products and are focused on rolling these out globally.

Download a PDF version of this job offer including contact details HERE.

Apply
Project Manager

Location: Anywhere

view vacancy

We are currently looking for a Project Manager. The successful candidate will be responsible for managing, coordinating, and delivering product development programs from an early-stage development phase until filing to Health Authorities, launch and routine commercial manufacturing.

Job description

In a matrix organization, as Project Manager, you will:

  • Work together with project team members and research scientists who would take on all scientific and technical matters in experimental study designs.
  • Prepare target product profiles, project development plans and budgets.
  • Prepare and keep up-to-date project timelines and costs and provide input for financial planning.
  • Organize efficient external and internal communication (periodic calls, ad-hoc calls, check lists, work specifications).
  • Co-ordinate external and internal project responsibilities against objectives and within budget.
  • Act as an internal or external point of contact with awareness of technical milestones and timelines as well as contractual obligations.
  • Assist with the preparation of requests for proposals and project proposals.
  • Monitor progress of individual projects, anticipate and manage risks and use or develop appropriate metrics as required.
  • Prepare stage-gate reports for e.g. project strategy, progress, issues, risks, updated timelines and costs.

Your professional profile

  • Minimum Qualification: MSc or PhD in Pharmacy, Chemistry or equivalent.
  • Minimum Experience: 7 years’ experience in pharmaceutical product development and project management.
  • Languages: English (written and verbal) – French is an asset.
  • Experienced Microsoft Project software user.
  • Ability to understand commercial contracts.

Your abilities

  • Demonstrate strong work ethics, and effective written and verbal communication skills.
  • Show an organizational aptitude to be part of an outstanding team.
  • Be flexible and have a strong team player attitude with the ability to motivate and to inject energy into the project teams.
  • Have strong interpersonal skills and a collaborative and trust enabling working style for building partnerships among key stakeholders.
  • Have the adaptability, flexibility, independence and resourcefulness to both lead a big vision strategy while also willing to roll-up-sleeves and multi-task to thrive in a growing environment.
  • Show respect for individuals and cultural difference across different countries.
  • Demonstrate efficient utilization of time and resources.
  • Be proactive and result-oriented with a focus on business.
  • Can steer external partners.

About Our Company

Hyloris is a specialty biopharma company focused on innovating, reinventing, and optimising existing medications to address important healthcare needs and deliver relevant improvements for patients, healthcare professionals and payors. Hyloris has built a broad, patented portfolio of 13 reformulated and repurposed value-added medicines that have the potential to offer significant advantages over available alternatives. Outside of its core strategic focus, the Company also has 3 high barrier generic products in development and registration phase. Two products are currently in initial phases of commercialisation with partners: Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a non-opioid post-operative pain treatment. The Company’s development strategy primarily focuses on the FDA’s 505(b)2 regulatory pathway, which is specifically designed for pharmaceuticals for which safety and efficacy of the molecule have already been established. This pathway can reduce the clinical burden required to bring a product to market, and significantly shorten the development timelines and reduce costs and risks. Hyloris is based in Liège, Belgium. For more information, visit www.hyloris.com and follow-us on LinkedIn.

Our values

Our talented staff work in accordance with our company values:

  • We are proud of our entrepreneurial culture and foster open communication, mutual respect, professionalism and efficient decision-making and we believe that our multicultural organisation is one of our most important competitive advantage.
  • We believe that timely and well considered decisions as a response to emerging opportunities and ideas is the key to our success.
  • We believe that the success of the company lies in the competence, dedication, and motivation of each of our employees.
  • We believe that freedom returns flexibility and empowerment returns commitment.

Download a PDF version HERE

 

Apply
IP Manager

Location: Anywhere

view vacancy

We are currently looking for an IP Manager. The successful candidate will be responsible for overseeing a diverse portfolio of intellectual property rights from disclosure to protection which requires constant follow-up.

Job description

As an IP Manager you will:

  • review new invention disclosures and provide assessment regarding patentability
  • manage an IP portfolio for a wide range of products
  • liaise with patent attorneys and service providers
  • be in charge of carrying out or organizing patent searches
  • initiate and monitor the patent protection process
  • follow-up the patent prosecution
  • follow-up the administrative part for obtaining and maintaining a patent
  • instruct external agencies timely on procedural actions
  • closely monitor costs

Your professional profile

  • Keen interest in intellectual property, especially patent protection.
  • Experience in intellectual property and/or training in patent law
  • Research Experience (e.g. during a PhD) is a plus
  • Effective verbal and written communication skills (very good English – written and spoken, French and/or other languages are an asset)
  • Computer skills: Microsoft Office (Word, Excel, PowerPoint, Teams) and experience with an IP document management system

Your abilities  

  • Flexibility to work in a continuously changing start-up environment
  • High ethical standards with demonstrated experience handling highly sensitive information
  • Be flexible and have a strong team player attitude with the ability to motivate and to inject energy into the project teams.
  • People-centric professional with excellent attention to detail and capable of working in a structured way
  • Have strong interpersonal skills and a collaborative and trust enabling working style for building partnerships among key stakeholders.
  • Have the adaptability, flexibility, independence and resourcefulness to roll-up-sleeves and multi-task to thrive in a growing environment.
  • Enjoy investigating and digging deeper to find answers/solutions
  • Have affinity for legal proceedings and its rules and deadlines
  • Show respect for individuals and cultural difference across different countries.
  • Demonstrate efficient utilization of time and resources.
  • Be proactive and result-oriented with a focus on business.

About Our Company

Hyloris is a specialty biopharma company focused on innovating, reinventing, and optimising existing medications to address important healthcare needs and deliver relevant improvements for patients, healthcare professionals and payors. Hyloris has built a broad, patented portfolio of 13 reformulated and repurposed value-added medicines that have the potential to offer significant advantages over available alternatives. Two products are currently in initial phases of commercialisation with partners: Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a non-opioid post-operative pain treatment. The Company’s development strategy primarily focuses on the FDA’s 505(b)2 regulatory pathway, which is specifically designed for pharmaceuticals for which safety and efficacy of the molecule have already been established. This pathway can reduce the clinical burden required to bring a product to market, and significantly shorten the development timelines and reduce costs and risks. Hyloris is based in Liège, Belgium. For more information, visit www.hyloris.com and follow-us on LinkedIn.

Our values

Our talented staff work in accordance with our company values:

  • We are proud of our entrepreneurial culture and foster open communication, mutual respect, professionalism and efficient decision-making and we believe that our multicultural organisation is one of our most important competitive advantages.
  • We believe that timely and well considered decisions as a response to emerging opportunities and ideas is the key to our success.
  • We believe that the success of the company lies in the competence, dedication, and motivation of each of our employees.
  • We believe that freedom returns flexibility and empowerment returns commitment.

Download a PDF version HERE

Apply